QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.